Dosage Chart

TB-500 Dosage Chart

TB-500 dosage chart — reconstitution of a 10 mg vial, weekly loading and maintenance protocols with exact unit math, and the long-half-life caveat.

Last updated · 2026-08-04
Where to buy TB-500
TB-50012 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →

VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.

Reconstitution

10 mg TB-500 vial in 2 mL bacteriostatic water

Reconstituted at 10 mg / 2 mL, the vial holds 5 mg/mL. On a U-100 syringe, 50 units = 0.5 mL = 2.5 mg; 100 units = 1 mL = 5 mg. TB-500 uses larger, less frequent doses than the daily peptides.

The TB-500 dosage chart covers reconstitution of a 10 mg vial and the weekly loading and maintenance protocols below, with the exact unit math for each dose. TB-500 is a systemic repair peptide with a long half-life, so it is dosed weekly rather than daily.

Dosage protocols

Maintenance

50 units · 0.5 mL · 2.5 mg TB-500
Once weekly
Cycle: 4 weeks maintenance, then reassess

After loading, 2.5 mg once weekly maintains levels. The long half-life means the compound accumulates — space doses and cycle rather than dosing daily.

Your vial, your numbers

Different vial size or water volume? Recalculate your exact draw.

TB-500 blend

Syringe Size

Draw to mark

50u(0.500 mL)

Concentration

5000 mcg / mL

For research purposes only. Verify all calculations independently before use.

020406080100
50u
100u syringe

From vial to injection

  1. Sanitize Wipe the TB-500 vial stopper and the bacteriostatic-water stopper with fresh alcohol swabs and let them dry.
  2. Draw the diluent Draw 2 mL of bacteriostatic water into a reconstitution syringe.
  3. Add water slowly Angle the needle so the water runs down the inside wall of the vial rather than onto the powder.
  4. Swirl, don't shake Gently swirl until fully dissolved. Never shake.
  5. Draw your dose With a U-100 insulin syringe, draw to 50 units (0.5 mL = 2.5 mg). A full 5 mg dose is 100 units (1 mL).
  6. Inject subcutaneously TB-500 is systemic — inject subcutaneously anywhere (abdomen or flank), not site-specific like BPC-157. Store reconstituted vial at 2–8 °C, use within 28 days.

Feeling something? Check here

Normal — expected
  • Mild, transient injection-site redness or a small welt that fades within an hour
  • Brief head-rush or fatigue after a loading dose
Back off & reassess
  • Persistent lethargy or headache during loading — extend the interval between doses
  • Injection-site lumps or bruising lasting more than a day — rotate sites, check technique
Stop & seek care
  • Facial/throat swelling, difficulty breathing, hives — stop and seek emergency care
  • Signs of injection-site infection — spreading redness, heat, pus, fever
  • Any new or growing lump elsewhere — growth/repair peptides are contraindicated with active or suspected cancer

Anchored to a phase-1 thymosin β4 trial (54 healthy volunteers, 0.05–25 mcg/kg IV) that reported mild-to-moderate adverse events with no dose-limiting toxicity.

This self-check is educational, not a diagnosis. When in doubt, stop dosing and consult a qualified healthcare provider.

Frequently Asked Questions

How do you dose TB-500?
Reconstitute a 10 mg vial with 2 mL bacteriostatic water (5 mg/mL). A common protocol loads 2.5 mg twice weekly (≈5 mg/week) for 4–8 weeks — 50 units on a U-100 syringe is 2.5 mg — then drops to 2.5 mg once weekly for maintenance. TB-500 is injected subcutaneously anywhere.
Why is TB-500 dosed weekly instead of daily?
TB-500 has a roughly 14-day half-life, so it accumulates. Twice-weekly loading then weekly maintenance keeps levels steady without daily injections and avoids over-accumulation — the opposite cadence from short-half-life peptides like BPC-157.
Is TB-500 FDA-approved?
No. TB-500 (thymosin β4 fragment) is research-use-only in the US and not on the 503A bulks list or in any FDA interim compounding category. Community dosing guides are a starting point, not medical advice.

Sources

⚠️ TB-500 side effects — common, serious & how to reduce them →

Full TB-500 research page →